ArticleDiscover oncology2025
Identification and validation of T cell senescence-related prognostic genes in gastric carcinoma and investigation of their potential regulatory mechanisms.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study aimed to identify prognostic genes associated with immunosenescence in gastric carcinoma (GC) and to elucidate their mechanisms to provide new ideas for the clinical treatment of GC.
methodsAccording to single cell data, clustering and annotation were conducted to acquire key cells. Then, differentially expressed genes (DEGs) in key cells (KC-DEGs) and TCGA-GC (GC-DEGs) were obtained, and took their intersection with CS-RGs to obtain candidate genes. Afterwards, prognostic genes were identified by regression analyses. Following this, the risk model was constructed, and the high-risk and low-risk groups were obtained. Next, a nomogram based on independent prognostic factors was constructed for predicting survival in GC. Finally, to further explore the mechanisms associated with the risk groups, immune microenvironment analysis was performed.
resultsT cells were used as key cells. Subsequently, AXL, PIM1, STK40, CXCL1, IFNG and SERPINE1 were identified as prognostic genes. The risk model and nomogram had favourable predictive capability in survival of GC patients. Surprisingly, 17 differential immune cells had higher levels of infiltration in the high-risk group, a result that was further confirmed in tumor purity. Notably, there was mostly a positive correlation between them and prognostic genes. Then, both tumor mutation burden (TMB) and microsatellite instability (MSI) were lower in the high-risk group, suggested the high-risk group might be associated with lower treatment benefit.
conclusion6 prognostic genes were identified, providing novel concepts in prognosis and therapy for GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.